Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Trial Profile

Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Suspended
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs Guadecitabine (Primary) ; Cisplatin
  • Indications Germ cell and embryonal neoplasms
  • Focus Adverse reactions
  • Most Recent Events

    • 18 May 2017 Planned End Date changed from 1 May 2018 to 31 Dec 2018.
    • 18 May 2017 Planned primary completion date changed from 1 May 2017 to 31 Dec 2017.
    • 18 May 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top